134 related articles for article (PubMed ID: 38634839)
1. Tolerability of Meropenem and Ertapenem in a Patient with Documented Delayed Hypersensitivity Reaction to Imipenem-Cilastatin: A Literature Review.
Laajimi R; Mansour K; Chadli Z; Ben Fredj N; Ben Romdhane H; Chaabane A; Aouam K
Dermatitis; 2024 Apr; ():. PubMed ID: 38634839
[No Abstract] [Full Text] [Related]
2. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams.
Schiavino D; Nucera E; Lombardo C; Decinti M; Pascolini L; Altomonte G; Buonomo A; Patriarca G
Allergy; 2009 Nov; 64(11):1644-8. PubMed ID: 19392998
[TBL] [Abstract][Full Text] [Related]
4. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
5. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
6. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
[TBL] [Abstract][Full Text] [Related]
7. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
13. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
14. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
15. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
Hou F; Wu G; Zheng B
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
[TBL] [Abstract][Full Text] [Related]
16. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
Edwards SJ; Clarke MJ; Wordsworth S; Welton NJ
Curr Med Res Opin; 2009 Jan; 25(1):251-61. PubMed ID: 19210156
[TBL] [Abstract][Full Text] [Related]
17. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
19. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P
Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165
[TBL] [Abstract][Full Text] [Related]
20. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
